ATE481985T1 - Immunpotenzierende zusammensetzungen - Google Patents

Immunpotenzierende zusammensetzungen

Info

Publication number
ATE481985T1
ATE481985T1 AT03741154T AT03741154T ATE481985T1 AT E481985 T1 ATE481985 T1 AT E481985T1 AT 03741154 T AT03741154 T AT 03741154T AT 03741154 T AT03741154 T AT 03741154T AT E481985 T1 ATE481985 T1 AT E481985T1
Authority
AT
Austria
Prior art keywords
cancer
compositions
substrates
infection treatment
treatment
Prior art date
Application number
AT03741154T
Other languages
English (en)
Inventor
Tasuku Honjo
Nagahiro Minato
Yoshiko Iwai
Shiro Shibayama
Original Assignee
Ono Pharmaceutical Co
Tasuku Honjo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30117379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481985(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ono Pharmaceutical Co, Tasuku Honjo filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of ATE481985T1 publication Critical patent/ATE481985T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
AT03741154T 2002-07-03 2003-07-02 Immunpotenzierende zusammensetzungen ATE481985T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002194491 2002-07-03
JP2003029846 2003-02-06
PCT/JP2003/008420 WO2004004771A1 (ja) 2002-07-03 2003-07-02 免疫賦活組成物

Publications (1)

Publication Number Publication Date
ATE481985T1 true ATE481985T1 (de) 2010-10-15

Family

ID=30117379

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03741154T ATE481985T1 (de) 2002-07-03 2003-07-02 Immunpotenzierende zusammensetzungen

Country Status (16)

Country Link
US (10) US7595048B2 (de)
EP (4) EP3287144A1 (de)
JP (9) JP4409430B2 (de)
AT (1) ATE481985T1 (de)
AU (1) AU2003281200A1 (de)
CY (1) CY20182200001T2 (de)
DE (2) DE60334303D1 (de)
DK (2) DK1537878T3 (de)
ES (2) ES2654064T3 (de)
FI (1) FI2206517T3 (de)
FR (2) FR15C0088I1 (de)
HU (3) HUE065675T2 (de)
LU (2) LU92905I2 (de)
PT (2) PT1537878E (de)
SI (1) SI2206517T1 (de)
WO (1) WO2004004771A1 (de)

Families Citing this family (822)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL147972A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Ge Pd-1, a receptor for b7-4 and uses therefor
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
PT1537878E (pt) * 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
SI3428191T1 (sl) * 2004-10-06 2025-03-31 Mayo Foundation For Medical Education And Research B7-H1 in PD-1 v zdravljenju karcinoma ledvičnih celic
CN103059138B (zh) * 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
CA2607291A1 (en) 2005-05-12 2006-11-23 Steven D. Levin Compositions and methods for modulating immune responses
RU2596491C2 (ru) * 2005-06-08 2016-09-10 Дана-Фарбер Кэнсер Инститьют Способы и композиции для лечения персистирующих инфекций
AU2012204032B2 (en) * 2005-06-08 2014-01-16 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
WO2007005874A2 (en) * 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CN101501062B (zh) * 2005-07-26 2012-07-18 康哲医药研究(深圳)有限公司 新型生物活性肽及其新用途
EP1777523A1 (de) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) In-vitro-Verfahren zur Prognose einer Tumorprogression und des Ergebnisses bei einem Patienten sowie Mittel zur Durchführung dieses Verfahrens
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
WO2007082154A2 (en) * 2006-01-05 2007-07-19 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP2889309B1 (de) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer der extrazelluläre domäne des pd-1 oder pd-l1
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
ES2918323T3 (es) 2006-05-31 2022-07-15 Childrens Medical Center Células madre mesenquimatosas ABC5 positivas como inmunomoduladores
AU2007342338A1 (en) * 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
AR063086A1 (es) 2006-10-02 2008-12-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
JP5623747B2 (ja) * 2006-12-27 2014-11-12 エモリー ユニバーシティ 感染症および腫瘍を処置するための組成物および方法
SI2155248T1 (sl) 2007-04-12 2015-12-31 The Brigham And Women's Hospital, Inc. Ciljanje ABCB5 za zdravljenje raka
EP3222634A1 (de) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antikörper zum humanen programmierten zelltod-pd-1-rezeptor
EP2514762B1 (de) 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC-Varianten
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
SI2279412T1 (sl) 2008-04-09 2017-10-30 Genentech, Inc., Novi sestavki in postopki za zdravljenje imunsko povezanih bolezni
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
WO2010001617A1 (en) * 2008-07-04 2010-01-07 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human pd-1 antibody on cancers
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BRPI0917891A2 (pt) * 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
US20110287034A1 (en) 2008-11-14 2011-11-24 The Brigham And Womens Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010063011A2 (en) 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
NZ717213A (en) * 2008-12-09 2017-10-27 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
JPWO2010101249A1 (ja) * 2009-03-06 2012-09-10 国立大学法人三重大学 Ｔ細胞の機能増強方法
JP5551683B2 (ja) 2009-03-30 2014-07-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 リポソーム組成物
JP5836940B2 (ja) 2009-06-26 2015-12-24 ソリシメド・バイオファーマ・インコーポレーテッド ソリシジン由来ペプチドならびにｔｒｐｖ−６がんの検出および薬剤送達のための方法
CN102740887B (zh) 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
LT2504364T (lt) * 2009-11-24 2017-11-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US9783578B2 (en) 2010-06-25 2017-10-10 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP2683400A4 (de) 2011-03-11 2014-09-17 Advaxis Adjuvanzien auf listerien-basis
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
CN102250910B (zh) * 2011-05-31 2013-01-30 苏州大学 一种人可溶性b7-dc定量检测试剂盒
EP2717895A1 (de) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutische verbindungen für immunmodulation
RU2641256C2 (ru) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Гетеродимеризованный полипептид
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
AU2012322999B2 (en) 2011-10-11 2017-08-10 Universitat Zurich Prorektorat Mnw Combination medicament comprising IL-12 and an agent for blockade of T-cell inhibitory molecules for tumour therapy
HRP20220924T1 (hr) * 2011-10-17 2022-10-28 Io Biotech Aps Imunoterapija zasnovana na pd-l1
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
BR112014006314A2 (pt) 2011-10-21 2017-04-11 Abbvie Inc métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
ES2808152T3 (es) * 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
WO2013090552A1 (en) * 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2013107791A1 (en) 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
CN104220462A (zh) 2012-02-16 2014-12-17 Vlp治疗有限责任公司 病毒样颗粒组合物
CN104159911A (zh) 2012-03-07 2014-11-19 奥瑞基尼探索技术有限公司 作为免疫调节剂的模拟肽化合物
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
EP2831108A1 (de) * 2012-03-29 2015-02-04 Aurigene Discovery Technologies Limited Cyclische immunmodulierende verbindungen aus der bc-schleife von menschlichem pd1
JP6378170B2 (ja) 2012-04-12 2018-08-22 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 異なる医薬品の制御送達のためのビヒクル
HK1203971A1 (en) * 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
DK3473707T3 (da) * 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
FI3421486T3 (fi) 2012-06-22 2023-12-15 Dartmouth College Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN112587658A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP2892558B1 (de) * 2012-09-07 2019-04-10 The Trustees Of Dartmouth College Vista-modulatoren zur diagnose und behandlung von krebs
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
WO2014124217A1 (en) * 2013-02-07 2014-08-14 Albert Einstein College Of Medicine Of Yeshiva University A selective high-affinity immune stimulatory reagent and uses thereof
US20150377891A1 (en) 2013-02-07 2015-12-31 (Institute National De La Santé Et De La Rechere Médicale) Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas
DK2958588T3 (da) 2013-02-22 2017-11-20 Curevac Ag Kombination af vaccination og hæmning af PD-1-reaktionsvejen
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2014169078A2 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
CN105339389B (zh) 2013-05-02 2021-04-27 安奈普泰斯生物有限公司 针对程序性死亡-1(pd-1)的抗体
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
WO2014194302A2 (en) * 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US9637532B2 (en) 2013-07-12 2017-05-02 Vlp Therapeutics, Llc Virus like particle comprising PD-1 antigen or PD-1 ligand antigen
KR20250007687A (ko) * 2013-07-16 2025-01-14 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
CN105849092A (zh) 2013-09-06 2016-08-10 奥瑞基尼探索技术有限公司 作为免疫调节剂的1，3，4-*二唑和1，3，4-噻二唑衍生物
HRP20181271T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Ciklički peptidomimetički spojevi kao imunomodulatori
EP3363790B1 (de) 2013-09-06 2020-02-19 Aurigene Discovery Technologies Limited 1,2,4-oxadiazolderivate als immunmodulatoren
DK3044234T3 (da) 2013-09-13 2020-05-18 Beigene Switzerland Gmbh Anti-PD1-antistoffer og anvendelse deraf som terapeutika og diagnostika
PT3508502T (pt) 2013-09-20 2023-06-22 Bristol Myers Squibb Co Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
EP3052131B1 (de) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Verfahren zur krebsbehandlung bei patienten mit erhöhtem bim-spiegel
US9884026B2 (en) 2013-11-01 2018-02-06 Yale University Modular particles for immunotherapy
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
PT3083694T (pt) 2013-12-20 2024-02-01 Intervet Int Bv Anticorpos murinos caninizados anti-pd-1 canino
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CN114163529B (zh) 2013-12-24 2024-12-13 杨森制药公司 抗vista抗体及片段
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP2017503803A (ja) 2014-01-10 2017-02-02 シャンハイ バーディー バイオテック インコーポレイテッド Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物
CN113603788B (zh) 2014-01-15 2025-05-09 卡德门企业有限公司 免疫调节剂
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
US9683048B2 (en) 2014-01-24 2017-06-20 Novartis Ag Antibody molecules to PD-1 and uses thereof
ME03489B (de) 2014-01-31 2020-01-20 Novartis Ag Antikörpermoleküle mit tim-3 und verwendungen davon
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
TW201613635A (en) 2014-02-04 2016-04-16 Pfizer Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
SG11201606428UA (en) 2014-02-04 2016-09-29 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
NZ725006A (en) 2014-03-12 2019-11-29 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
ES2754239T3 (es) 2014-03-12 2020-04-16 Curevac Ag Combinación de vacunación y agonistas de OX40
JP6576962B2 (ja) 2014-03-14 2019-09-18 ノバルティス アーゲー Ｌａｇ−３に対する抗体分子およびその使用
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
CA2947939A1 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
EP3760208B1 (de) 2014-06-25 2024-05-29 The General Hospital Corporation Targeting von humanem satellit ii (hsatii)
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
EP3166976B1 (de) 2014-07-09 2022-02-23 Birdie Biopharmaceuticals Inc. Anti-pd-l1-kombinationen zur tumorbehandlung
EP3168236B1 (de) 2014-07-09 2019-09-04 Nippon Zenyaku Kogyo Co., Ltd. Anti-canin-pd-1-antikörper oder anti-canin-pd-1l-antikörper
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
CN114984228A (zh) 2014-07-18 2022-09-02 阿德瓦希斯股份有限公司 用于治疗前列腺癌的pd-1拮抗剂和基于李斯特菌的疫苗的组合
SG10201900571YA (en) 2014-07-22 2019-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
US11186640B2 (en) * 2014-07-31 2021-11-30 The University Of Western Australia Method for the identification of immunotherapy-drug combinations using a network approach
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
US9982053B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
MX390385B (es) 2014-08-05 2025-03-20 Cb Therapeutics Inc Anticuerpos anti-pd-l1.
AU2015300006B2 (en) * 2014-08-07 2018-08-30 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CA2958573A1 (en) * 2014-08-19 2016-02-25 National University Corporation Okayama University Agent for treating and/or preventing diseases associated with immune abnormalities by combining biguanide antidiabetic drug with immunosuppressive factor blocking agent or costimulatory receptor agonist
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
US10098943B2 (en) 2014-09-11 2018-10-16 Vlp Therapeutics, Llc Flavivirus virus like particle
EP3191126B1 (de) 2014-09-13 2020-05-13 Novartis AG Kombinationstherapien aus alk-hemmern
US10039564B2 (en) 2014-09-30 2018-08-07 Ethicon Llc Surgical devices having power-assisted jaw closure and methods for compressing and sensing tissue
US10550194B2 (en) 2014-09-30 2020-02-04 Intervet Inc. PD-L1 antibodies binding canine PD-L1
KR20170072244A (ko) 2014-10-10 2017-06-26 이데라 파마슈티칼즈, 인코포레이티드 관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료
EP3206711B1 (de) 2014-10-14 2023-05-31 Novartis AG Antikörpermoleküle gegen pd-l1 und verwendungen davon
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
MX2017007321A (es) * 2014-12-02 2017-08-25 Celgene Corp Terapias de combinacion.
EP3226688B1 (de) 2014-12-05 2020-07-01 Merck Sharp & Dohme Corp. Tricyclische verbindungen als inhibitoren von mutanten idh-enzymen
WO2016089833A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
US10508108B2 (en) 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
WO2016094273A1 (en) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
CN107257624B (zh) * 2014-12-09 2021-07-13 瑞泽恩制药公司 具有人源化分化簇274基因的非人动物
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
US10849862B2 (en) 2014-12-26 2020-12-01 Theravalues Corporation Formulation of curcumin and anti-PD-1 antibody
CN107428813B (zh) 2014-12-31 2021-08-03 查克美特制药公司 组合肿瘤免疫疗法
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3252469A1 (de) * 2015-01-29 2017-12-06 Konica Minolta, Inc. Verfahren zur gleichzeitigen erkennung von blutzellen mit interagierenden molekülen
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
CN107635582B (zh) * 2015-02-12 2022-08-02 约翰·霍普金斯大学 用于阻断肿瘤免疫耐受性的yap抑制
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
CN107810013B (zh) 2015-03-04 2021-04-02 默沙东公司 用于治疗癌症的pd-1拮抗剂和艾立布林的组合
LT3267984T (lt) 2015-03-10 2022-03-25 Aurigene Discovery Technologies Limited 1,2,4-oksadiazolo ir tiadiazolo junginiai kaip imunomoduliatoriai
KR20170135860A (ko) 2015-03-13 2017-12-08 싸이톰스 테라퓨틱스, 인크. 항-pdl1 항체, 활성화 가능한 항-pdl1 항체, 및 이들의 사용 방법
WO2016154177A2 (en) 2015-03-23 2016-09-29 Jounce Therapeutics, Inc. Antibodies to icos
EP3277716B1 (de) 2015-04-03 2020-06-24 XOMA Technology Ltd. Behandlung von krebs unter verwendung von inhibitoren von tgf-beta und pd-1
EA201792273A1 (ru) 2015-04-17 2018-04-30 Бристол-Маерс Сквибб Компани Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
KR20240149980A (ko) 2015-04-28 2024-10-15 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 항-ctla-4 항체를 사용한 pd-l1-음성 흑색종의 치료
DK3298021T3 (da) 2015-05-18 2019-08-05 Tolero Pharmaceuticals Inc Alvocidib-prodrugs, der har øget biotilgængelighed
HK1252245A1 (zh) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
AU2016271018A1 (en) 2015-05-29 2017-11-30 Dynavax Technologies Corporation Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
KR20230028478A (ko) 2015-05-29 2023-02-28 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
MX381587B (es) * 2015-05-29 2025-03-12 Dynavax Tech Corp Agonistas de polinucleótidos del receptor 9 tipo toll y composiciones farmacéuticas de los mismos.
JP2018521979A (ja) 2015-06-03 2018-08-09 ボストン バイオメディカル， インコーポレイテッド 癌の治療に使用するための癌幹細胞性阻害剤および免疫療法剤を含む組成物
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
JP6757959B2 (ja) * 2015-06-16 2020-09-23 株式会社 ＰＲＩＳＭ ＢｉｏＬａｂ 抗がん剤
JP6876629B2 (ja) 2015-06-16 2021-05-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｐｄ−ｌ１アンタゴニスト併用療法
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
CN114344462B (zh) * 2015-06-24 2024-08-13 英摩杜伦治疗学公司 用于癌症治疗的检查点抑制剂和全细胞分枝杆菌
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
EA201890285A1 (ru) 2015-07-13 2018-08-31 Сайтомкс Терапьютикс, Инк. Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PT3322731T (pt) 2015-07-14 2021-02-25 Bristol Myers Squibb Co Método de tratamento de cancro utilizando inibidor de ponto de verificação (checkpoint) imunitário; anticorpo que se liga ao recetor de morte programada-1 (pd-1) ou ligando de morte programada 1 (pd-l1)
EP3322431A2 (de) 2015-07-16 2018-05-23 Biokine Therapeutics Ltd. Zusammensetzungen und verfahren zur behandlung von krebs
MA58293B1 (fr) 2015-07-30 2024-11-29 Macrogenics, Inc. Molécules de liaison pd-1 et leurs procédés d'utilisation
HK1254976A1 (zh) 2015-07-31 2019-08-02 University Of Florida Research Foundation, Inc. 造血干细胞和抗癌免疫检查点抑制剂的组合疗法
US20180222989A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP3331916A1 (de) 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlungen sowie verwendungen und verfahren davon
RU2018107991A (ru) 2015-08-07 2019-09-09 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Новый слитый полипептид, специфичный в отношении lag-3 и pd-1
EP3331919A1 (de) 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie mit anti-ctla-4-antikörpern
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
PL3334763T3 (pl) 2015-08-11 2024-12-02 WuXi Biologics Ireland Limited Nowe przeciwciała anty-pd-1
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
TWI696629B (zh) 2015-08-13 2020-06-21 美商默沙東藥廠 作為ｓｔｉｎｇ促效劑之環狀雙核苷酸化合物
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
WO2017038997A1 (ja) 2015-09-03 2017-03-09 小野薬品工業株式会社 Ａｌｌｅｒｇｉｎ－１アンタゴニストによるがん免疫増強剤
US11124569B2 (en) * 2015-09-18 2021-09-21 Dana-Farber Cancer Institute, Inc. Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
JP6949009B2 (ja) * 2015-09-21 2021-10-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒトプログラム死リガンド２（ｐｄ−ｌ２）に結合する抗体およびその用途
JP6933379B2 (ja) * 2015-09-24 2021-09-08 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 転移を低減するための方法および組成物
CN113912724B (zh) 2015-09-25 2025-03-14 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
US10428145B2 (en) 2015-09-29 2019-10-01 Celgene Corporation PD-1 binding proteins and methods of use thereof
EP3356551B1 (de) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur bestimmung der stoffwechsellage von b-lymphomen
JP6952028B2 (ja) * 2015-09-29 2021-10-20 シャンハイ チャンジアン バイオテクノロジー カンパニー リミテッド Ｐｄ−１抗体およびその使用
MY192202A (en) 2015-10-02 2022-08-06 Hoffmann La Roche Bispecific antibodies specific for pd1 and tim3
RS62450B1 (sr) 2015-10-02 2021-11-30 Hoffmann La Roche Anti-pd1 antitela i postupci primene
GEAP202114756A (en) 2015-10-08 2021-07-26 Macrogenics Inc Combination therapy for the treatment of cancer
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
EP3365372A1 (de) 2015-10-22 2018-08-29 Jounce Therapeutics, Inc. Gensignaturen zur bestimmung der icos-expression
JP6921067B2 (ja) * 2015-10-28 2021-08-18 イエール ユニバーシティ ヒト化抗Ｄｋｋ２抗体およびその使用方法
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
HUE057837T2 (hu) 2015-11-03 2022-06-28 Janssen Biotech Inc PD-1-et specifikusan kötõ ellenanyagok és alkalmazásaik
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
PL3373959T3 (pl) * 2015-11-12 2022-10-24 Hookipa Biotech Gmbh Cząstki arenawirusa jako szczepionki przeciwrakowe
PT3377534T (pt) 2015-11-18 2025-07-10 Bristol Myers Squibb Co Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4
BR112018011228A2 (pt) 2015-12-01 2019-01-15 Glaxosmithkline Intellectual Property Development Limited tratamentos de combinação e seus usos e métodos
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
EP3366691A1 (de) 2015-12-03 2018-08-29 GlaxoSmithKline Intellectual Property Development Limited Cyclische purin dinukleotide als sting-modulatoren
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
WO2017106062A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
GB201522311D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
DK3390451T3 (da) 2015-12-18 2025-03-17 Intervet Int Bv Kaniniserede humane antistoffer mod il-4r-alpha hos mennesker og hunde
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
EP3400443B1 (de) 2016-01-04 2020-09-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Verwendung von pd-1 und tim-3 zur messung von cd8+ zellen zur vorhersage und behandlung von nierenzellkarzinom
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
MA43590A (fr) 2016-01-08 2018-11-14 Taiho Pharmaceutical Co Ltd Agent antitumoral contenant un immunomodulateur et un amplificateur d'effet antitumoral
CN109195988B (zh) 2016-01-10 2023-12-01 尼奥克斯医疗有限公司 用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
WO2017125815A2 (en) 2016-01-22 2017-07-27 MabQuest SA Immunological reagents
CN108883180B (zh) 2016-02-05 2023-07-07 奥里尼斯生物科学私人有限公司 Clec9a结合剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
EP3213768A1 (de) 2016-03-01 2017-09-06 LODOCO CLINICAL Kft Kombination von einer niedrig dosierten immunologischen checkpoint blockade mit einetr hoch dosierten il-2 dosis zur behandlung von metastatierndem tumoren
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
JP7085985B2 (ja) 2016-03-04 2022-06-17 大鵬薬品工業株式会社 悪性腫瘍治療用製剤及び組成物
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017155981A1 (en) 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
CN108778301A (zh) 2016-03-10 2018-11-09 永恒生物科技股份有限公司 通过联合疗法来治疗实体瘤或淋巴瘤的方法
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
CN114717235A (zh) * 2016-03-14 2022-07-08 豪夫迈·罗氏有限公司 用于减少pd-l1表达的寡核苷酸
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
KR102413037B1 (ko) 2016-03-15 2022-06-23 메르사나 테라퓨틱스, 인코포레이티드 Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법
TWI762473B (zh) * 2016-03-30 2022-05-01 中天生物科技股份有限公司 以免疫檢測點調節劑以及由共生微生物菌叢之發酵產物的結合癌症療法
EP3436066A1 (de) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc-rezeptor-vermittelte wirkstofffreisetzung
US11209441B2 (en) 2016-04-05 2021-12-28 Bristol-Myers Squibb Company Cytokine profiling analysis
BR112018070602A2 (pt) 2016-04-07 2019-02-05 Glaxosmithkline Ip Dev Ltd composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
PL3440076T3 (pl) 2016-04-07 2022-09-05 Glaxosmithkline Intellectual Property Development Limited Heterocykliczne amidy przydatne jako modulatory białek
AU2017250294B2 (en) 2016-04-15 2022-07-21 Immunext Inc. Anti-human VISTA antibodies and use thereof
EP3449921B1 (de) 2016-04-28 2023-05-31 Eisai R&D Management Co., Ltd. Eribulin zur hemmung des tumorwachstums
CN109689063B (zh) 2016-04-28 2026-02-27 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
WO2017191545A1 (en) 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
TWI755395B (zh) 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3243832A1 (de) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigenbindende moleküle mit einem ligandentrimer der tnf-familie und pd1-bindungsteil
EP3455245A2 (de) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutisches targeting von nichtzellulären strukturen
WO2017201043A1 (en) * 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer
EP3458485B1 (de) 2016-05-19 2021-12-29 The General Hospital Corporation An den rezeptor il-2rbeta gebundenes interleukin-2, eine plattform zur erhöhung der aktivität von natürlichen killer- und regulatorischen t-zellen
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
CA3025887C (en) 2016-05-31 2022-06-28 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
NZ748650A (en) * 2016-06-02 2025-11-28 Bristol Myers Squibb Co Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment
LT3463457T (lt) 2016-06-02 2023-09-11 Bristol-Myers Squibb Company Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
US20190292260A1 (en) 2016-06-03 2019-09-26 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
WO2017212425A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
CN109563034A (zh) 2016-06-08 2019-04-02 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
US9567399B1 (en) * 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2017220602A1 (en) 2016-06-21 2017-12-28 Herlev Hospital Pdl1 peptides for use in cancer vaccines
EP3476865B1 (de) 2016-06-28 2023-09-13 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Verfahren zur erstellung eines pd-1-gen-modifizierten humanisierten tiermodells und verwendung davon
WO2018006005A1 (en) 2016-06-30 2018-01-04 Oncorus, Inc. Pseudotyped oncolytic viral delivery of therapeutic polypeptides
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
KR20190044070A (ko) 2016-08-03 2019-04-29 넥스트큐어 인코포레이티드 Lair 신호 변환을 조정하기 위한 조성물 및 방법
WO2018025221A1 (en) 2016-08-04 2018-02-08 Glaxosmithkline Intellectual Property Development Limited Anti-icos and anti-pd-1 antibody combination therapy
KR20230044038A (ko) 2016-08-09 2023-03-31 키맵 리미티드 항-icos 항체
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
EP3500294A4 (de) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation Anti-pd-1-antikörper oder fragmente davon zur behandlung von hepatitis b
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
JP7045378B2 (ja) 2016-09-01 2022-03-31 キメラ・バイオエンジニアリング，インコーポレーテッド Ｇｏｌｄ最適化ＣＡＲ Ｔ細胞
HRP20201993T1 (hr) 2016-09-14 2021-02-05 Abbvie Biotherapeutics Inc. Protutijela protiv pd-1
JP2019533645A (ja) 2016-09-16 2019-11-21 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的組織および細胞内送達のための増大した粘膜浸透のタンパク質ナノケージ
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
EP3515943A4 (de) 2016-09-19 2020-05-06 Celgene Corporation Verfahren zur behandlung von vitiligo mithilfe von pd-1-bindenden proteinen
WO2018057735A1 (en) 2016-09-21 2018-03-29 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
EP4360714A3 (de) 2016-09-21 2024-07-24 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
WO2018064013A1 (en) 2016-09-27 2018-04-05 Peregrine Pharmaceuticals, Inc. METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
CN110036001B (zh) 2016-10-04 2022-03-22 默沙东公司 作为STING激动剂的苯并[b]噻吩化合物
MX2019003755A (es) 2016-10-06 2019-08-12 Pfizer Regimen de dosificacion de avelumab para el tratamiento de cancer.
JP7213799B2 (ja) 2016-10-10 2023-01-27 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 非細胞傷害性改変細胞およびその使用
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
CN110072552A (zh) 2016-10-14 2019-07-30 默沙东公司 用于治疗尿路上皮癌的pd-1拮抗剂和艾立布林的组合
ES2917000T3 (es) 2016-10-24 2022-07-06 Orionis Biosciences BV Interferón-gamma mutante diana y usos del mismo
JP7420335B2 (ja) 2016-10-26 2024-01-23 デンカ株式会社 変異型ヒトＤＮＡポリメラーゼε
CA3041684C (en) 2016-11-01 2023-09-26 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (pd-1)
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
HUE057559T2 (hu) 2016-11-02 2022-06-28 Jounce Therapeutics Inc PD-1 elleni antitestek és alkalmazásaik
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3541825B1 (de) 2016-11-21 2026-04-01 Idenix Pharmaceuticals LLC Cyclische phosphatsubstituierte nukleosidderivate zur behandlung von lebererkrankungen
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP7126269B2 (ja) 2016-11-30 2022-08-26 メレオ バイオファーマ ５ インコーポレイテッド Ｔｉｇｉｔ結合物質を含む、がんの処置のための方法
BR112019011350A2 (pt) 2016-12-01 2019-10-22 Glaxosmithkline Ip Dev Ltd terapia de combinação
AU2017368923A1 (en) 2016-12-01 2019-06-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
EP3564678A4 (de) 2016-12-28 2020-08-12 Kinki University Verfahren zur auswahl von personen zur verabreichung eines immuncheckpoint-inhibitors
CN110382545A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗pd-1抗体治疗癌症的方法
JP2020503883A (ja) 2017-01-13 2020-02-06 アジェナス インコーポレイテッド Ｎｙ−ｅｓｏ−１に結合するｔ細胞受容体およびその使用方法
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EP3573989A4 (de) 2017-01-25 2020-11-18 Beigene, Ltd. Kristalline formen von (s)-7-(1-(but-2-ynoyl)-piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-3-carboxamid, herstellung und verwendungen davon
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
EP3582855A1 (de) 2017-02-15 2019-12-25 GlaxoSmithKline Intellectual Property Development Limited Kombinationstherapie zur behandlung von krebs
BR112019017738A2 (pt) 2017-02-27 2020-04-07 Glaxosmithkline Ip Dev Ltd combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto
US20180271996A1 (en) 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
CN110337305A (zh) 2017-02-28 2019-10-15 赛诺菲 治疗性rna
KR20250007025A (ko) 2017-03-09 2025-01-13 젠맵 에이/에스 Pd-l1에 대한 항체
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
EP3596469A1 (de) 2017-03-12 2020-01-22 Yeda Research and Development Co., Ltd. Verfahren zur diagnose und prognose von krebs
EP3600427A1 (de) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und zusammensetzungen zur behandlung von melanom
EP3604345B1 (de) 2017-03-31 2023-05-10 Toagosei Co., Ltd. Antitumor-peptid mit pd-1 signalsequenz und verwendung davon
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
US11285207B2 (en) 2017-04-05 2022-03-29 Hoffmann-La Roche Inc. Bispecific antibodies specifically binding to PD1 and LAG3
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TW202500588A (zh) 2017-04-13 2025-01-01 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
AU2018254626B2 (en) 2017-04-21 2023-12-21 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
CN108794467A (zh) 2017-04-27 2018-11-13 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
MA50957A (fr) 2017-05-01 2020-10-14 Agenus Inc Anticorps anti-tigit et leurs méthodes d'utilisation
EP3618871A4 (de) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. Formulierungen von anti-lag3-antikörpern und co-formulierungen von anti-lag3-antikörpern und anti-pd-1-antikörpern
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
MA48637A (fr) 2017-05-09 2021-03-17 Merck Sharp & Dohme Polythérapies pour le traitement du cancer
EP3621624B1 (de) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclische di-nukleotid-verbindungen als sting-agonisten
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
MX391414B (es) 2017-05-26 2025-03-21 Taiho Pharmaceutical Co Ltd Compuesto novedoso de bifenilo o sal del mismo.
TWI727173B (zh) 2017-05-26 2021-05-11 日商大鵬藥品工業股份有限公司 使用有新穎聯苯化合物之抗腫瘤效果增強劑
PL3631454T3 (pl) 2017-05-30 2024-01-29 Bristol-Myers Squibb Company Leczenie guzów lag-3 pozytywnych
MX2019012076A (es) 2017-05-30 2019-12-09 Bristol Myers Squibb Co Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1).
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP3630126A4 (de) 2017-06-02 2021-03-17 The Penn State Research Foundation Ceramid-nanoliposomen, zusammensetzungen und verfahren zur verwendung für die immuntherapie
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
BR112019025325A2 (pt) 2017-06-09 2020-06-23 Glaxosmithkline Intellectual Property Development Limited Métodos para tratar câncer, para fabricar um anticorpo anti-icos ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, para fabricar um anticorpo anti-pdl1 ou porção de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou fragmento de ligação a antígeno do mesmo, anticorpo anti-icos ou fragmento de ligação a antígeno do mesmo e um anticorpo anti-pd-l1 ou fragmento de ligação a antígeno do mesmo, uso de um anticorpo anti-icos ou porção de ligação a antígeno do mesmo e um anticorpo anti-pd1 ou porção de ligação a antígeno do mesmo, polinucleotídeo, vetor, e, célula hospedeira
KR20200015717A (ko) 2017-06-09 2020-02-12 프로비던스 헬스 앤드 서비시즈 - 오레곤 암 치료를 위한 인간 종양 반응성 t 세포의 확인을 위한 cd39 및 cd103의 활용
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag Il-1beta binding antibodies for use in treating cancer
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
EP3641812A1 (de) 2017-06-22 2020-04-29 Novartis AG Antikörpermoleküle gegen cd73 und verwendungen davon
JP2020524694A (ja) 2017-06-22 2020-08-20 ノバルティス アーゲー がんの処置における使用のためのＩＬ−１β結合性抗体
CA3067268A1 (en) 2017-06-23 2018-12-27 Birdie Biopharmaceuticals, Inc. Crystalline resiquimod monosulfate anhydrate and its preparation and uses
WO2019001417A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. IMMUNOTHERAPY FOR HEPATOCELLULAR CARCINOMA
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
HUE073476T2 (hu) 2017-06-30 2026-01-28 Taiho Pharmaceutical Co Ltd Rák kemoterápia azabiciklo-vegyület alkalmazásával
US20210145771A1 (en) 2017-07-03 2021-05-20 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
BR112020000086A2 (pt) 2017-07-03 2020-07-07 Glaxosmithkline Intellectual Property Development Limited derivados de 2-(4-clorofenóxi)-n-((1-(2-(4-clorofenóxi) etinazetidin-3-il) metil) acetamida e compostos relacionados como inibidores de atf4 para tratamento de câncer e outras doenças
KR20250025039A (ko) 2017-07-20 2025-02-20 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
AU2018311965A1 (en) 2017-08-04 2020-02-13 Merck Sharp & Dohme Llc Combinations of PD-1 antagonists and benzo[b]thiophene sting antagonists for cancer treatment
EP3661960A1 (de) 2017-08-04 2020-06-10 Genmab A/S An pd-l1 und cd137 bindende bindemittel und deren verwendung
CA3071538A1 (en) 2017-08-04 2019-02-07 Merck Sharp & Dohme Corp. Benzo[b]thiophene sting agonists for cancer treatment
SG11202001063QA (en) 2017-08-09 2020-03-30 Orionis Biosciences Inc Clec9a binding agents and use thereof
CA3069994A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Pd-1 and pd-l1 binding agents
CA3069930A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. Cd8 binding agents
IL272697B2 (en) 2017-08-18 2023-12-01 Adastra Pharmaceuticals Inc A polymorphic form of TG02
KR20200052327A (ko) 2017-09-04 2020-05-14 아게누스 인코포레이티드 혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
TW201922721A (zh) 2017-09-07 2019-06-16 英商葛蘭素史克智慧財產發展有限公司 化學化合物
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
SG11202002862RA (en) 2017-09-30 2020-04-29 Tesaro Inc Combination therapies for treating cancer
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
JP2020536869A (ja) 2017-10-06 2020-12-17 テサロ， インコーポレイテッド 併用療法およびその使用
KR102838640B1 (ko) 2017-10-11 2025-07-24 오리진 온콜로지 리미티드 3-치환된 1,2,4-옥사다이아졸의 결정질 형태
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
US20200239577A1 (en) 2017-10-15 2020-07-30 Bristol-Myers Squibb Company Methods of treating tumor
WO2019081983A1 (en) 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
US12275729B2 (en) 2017-11-01 2025-04-15 Merck Sharp & Dohme Llc Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
AU2018360386B2 (en) 2017-11-03 2023-11-09 Aurigene Oncology Limited Dual inhibitors of TIM-3 and PD-1 pathways
WO2019087092A1 (en) 2017-11-06 2019-05-09 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
CN110945361B (zh) * 2017-11-07 2024-01-09 J制药股份有限公司 抗pd-1/pd-l1抗体疗法显效性的预测和提高方法以及评价癌症恶性程度的方法
EP3707272A4 (de) 2017-11-09 2021-11-24 The Trustees of The University of Pennsylvania Extrazelluläre vesikelproteine und ihre verwendung zur krebsdiagnose, prognose der reaktion auf eine therapie und behandlung
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
BR112020008258B8 (pt) 2017-11-14 2023-01-31 Merck Sharp & Dohme Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
EP3717021A1 (de) 2017-11-27 2020-10-07 Mersana Therapeutics, Inc. Pyrrolobenzodiazepin-antikörper-konjugate
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
JP6846574B2 (ja) 2017-11-29 2021-03-24 大鵬薬品工業株式会社 スルホンアミド化合物およびその使用
CA3083949A1 (en) 2017-11-30 2020-06-06 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
MX2020005692A (es) 2017-12-01 2020-09-25 Sbi Pharmaceuticals Co Ltd Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario.
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
CA3085472A1 (en) 2017-12-19 2019-06-27 The Rockefeller University Human igg fc domain variants with improved effector function
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3727401A4 (de) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. Cyclische di-nukleotid-verbindungen als sting-agonisten
CN111742053A (zh) 2017-12-20 2020-10-02 Vlp 治疗有限责任公司 甲病毒属复制子颗粒
EP3727463A1 (de) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepin-antikörper-konjugate
US11865081B2 (en) 2017-12-29 2024-01-09 Virogin Biotech Canada Ltd. Oncolytic viral delivery of therapeutic polypeptides
US20210072244A1 (en) 2018-01-04 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
US11324774B2 (en) 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
EP3737408A1 (de) 2018-01-08 2020-11-18 Novartis AG Immunstimulierende rnas zur kombination mit einer chimären antigen-rezeptor-therapie
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
WO2019149716A1 (en) 2018-01-31 2019-08-08 F. Hoffmann-La Roche Ag Bispecific antibodies comprising an antigen-binding site binding to lag3
EP3746116A1 (de) 2018-01-31 2020-12-09 Novartis AG Kombinationstherapie unter verwendung eines chimären antigenrezeptors
CN112533613A (zh) 2018-02-06 2021-03-19 通用医疗公司 作为肿瘤免疫应答的生物标志物的重复rna
EP3752194A4 (de) 2018-02-13 2022-03-16 Checkmate Pharmaceuticals, Inc. Zusammensetzungen und verfahren für die tumorimmuntherapie
EP3752203A1 (de) 2018-02-13 2020-12-23 Novartis AG Chimäre antigenrezeptortherapie in kombination mit il-15r und il15
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
CA3091502A1 (en) 2018-02-23 2019-08-29 Eucure (Beijing) Biopharma Co., Ltd Anti-pd-1 antibodies and uses thereof
US20210002373A1 (en) 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
EP3765006A4 (de) 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. Arginasehemmer und verfahren zur verwendung
BR122022000386B1 (pt) 2018-03-14 2022-09-27 Surface Oncology, Inc Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos
JP6918204B2 (ja) 2018-03-19 2021-08-11 大鵬薬品工業株式会社 アルキル硫酸ナトリウムを含む医薬組成物
CN120173101A (zh) 2018-03-22 2025-06-20 表面肿瘤学有限责任公司 抗il-27抗体及其用途
TWI793294B (zh) 2018-04-03 2023-02-21 美商默沙東有限責任公司 Sting促效劑化合物
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
KR102890791B1 (ko) 2018-04-09 2025-11-24 체크메이트 파마슈티칼스, 인크. 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
WO2019200214A1 (en) 2018-04-13 2019-10-17 The Regents Of The University Of Michigan Compositions and methods for treating cancer
SG11202010011RA (en) 2018-04-17 2020-11-27 Celldex Therapeutics Inc Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
CN112105733B (zh) 2018-04-19 2024-10-29 查美特制药公司 合成rig-i样受体激动剂
EP3781687A4 (de) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. Neue substituierte rig-i-agonisten : zusammensetzungen und verfahren dafür
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
WO2019222359A1 (en) 2018-05-15 2019-11-21 Duke University Systems and methods for genetic manipulation of akkermansia species
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
US11352320B2 (en) 2018-05-31 2022-06-07 Merck Sharp & Dohme Corp. Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
US12331068B2 (en) 2018-05-31 2025-06-17 Peloton Therapeutics, Inc. Compositions and methods for inhibiting CD73
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
IL319456A (en) 2018-06-20 2025-05-01 Incyte Holdings Corp ANTI-PD-1 ANTIBODIES AND THEIR USES
CA3105750A1 (en) 2018-07-09 2020-01-16 Precigen, Inc. Fusion constructs and methods of using thereof
WO2020012339A1 (en) 2018-07-09 2020-01-16 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
ES2963694T3 (es) 2018-07-10 2024-04-01 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
JP2021530218A (ja) 2018-07-11 2021-11-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. 血液脳関門を超える薬剤の送達のための方法および組成物
MA53381A (fr) 2018-07-24 2021-06-02 Amgen Inc Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
CN112512559B (zh) 2018-07-26 2025-02-28 Atyr医药公司 用于治疗nrp2相关疾病的组合物和方法
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
EP3833391A4 (de) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. Gegen sirp1alpha gerichtete chimäre proteine und verwendungen davon
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
CA3106881A1 (en) 2018-08-27 2020-03-05 Pieris Pharmaceuticals Gmbh Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2020055702A1 (en) 2018-09-13 2020-03-19 Merck Sharp & Dohme Corp. Combination of pd-1 antagonist and lag3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
US12186350B2 (en) 2018-09-25 2025-01-07 National Cerebral And Cardiovascular Center Antitumor effect potentiator
JP7398680B2 (ja) 2018-10-09 2023-12-15 バイオコモ株式会社 抗がん剤、がん治療用医薬組成物、及びキット
IL282317B2 (en) 2018-10-17 2024-04-01 Biolinerx Ltd Treatment of metastatic pancreatic adenocarcinoma
WO2020081381A1 (en) 2018-10-17 2020-04-23 Merck Sharp & Dohme Corp. Novel arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
JP7467438B2 (ja) 2018-10-18 2024-04-15 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｒｓｖ抗体の製剤及びその使用方法
CA3117746A1 (en) 2018-10-22 2020-04-30 Glaxosmithkline Intellectual Property Development Limited Dosing
EP3873534A1 (de) 2018-10-29 2021-09-08 Mersana Therapeutics, Inc. Cystein-modifizierte antikörper-wirkstoff-konjugate mit peptidhaltigen linkern
EP3873532A1 (de) 2018-10-31 2021-09-08 Novartis AG Dc-sign-antikörper-arzneimittelkonjugate
WO2020092233A1 (en) 2018-10-31 2020-05-07 Merck Sharp & Dohme Corp. Anti-human pd-1 antibody crystals and methods of use thereof
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092183A1 (en) 2018-11-01 2020-05-07 Merck Sharp & Dohme Corp. Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
EP3877366B1 (de) 2018-11-06 2026-01-28 Merck Sharp & Dohme LLC Neuartige substituierte tricyclische verbindungen als indolamin-2,3-dioxygenase-inhibitoren
SG11202104300PA (en) 2018-11-06 2021-05-28 Genmab As Antibody formulation
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
KR20210119380A (ko) 2018-11-09 2021-10-05 피어리언 바이오사이언스즈, 엘엘씨 종양 미세환경의 조성을 결정하기 위한 방법 및 조성물
BR112021008795A2 (pt) 2018-11-13 2021-08-31 Compass Therapeutics Llc Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos
PL3880186T3 (pl) 2018-11-14 2024-07-22 Regeneron Pharmaceuticals, Inc. Doogniskowe podawanie inhibitorów pd-1 do leczenia raka skóry
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
BR112021009411A2 (pt) 2018-11-16 2021-08-17 Arqule, Inc. combinação farmacêutica para tratamento de câncer
WO2020103885A1 (en) 2018-11-19 2020-05-28 Beijing Biocytogen Co., Ltd Anti-pd-1 antibodies and uses thereof
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US12466831B2 (en) 2018-11-20 2025-11-11 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US12414952B2 (en) 2018-11-20 2025-09-16 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
US20230183379A1 (en) 2018-11-20 2023-06-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020112581A1 (en) 2018-11-28 2020-06-04 Merck Sharp & Dohme Corp. Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
CN113613724B (zh) 2018-11-30 2024-11-08 葛兰素史克知识产权开发有限公司 可用于hiv疗法的化合物
CN113329791A (zh) 2018-11-30 2021-08-31 默沙东公司 作为腺苷受体拮抗剂的9-取代的氨基三唑并喹唑啉衍生物、药物组合物及其用途
SG11202105689XA (en) 2018-12-03 2021-06-29 Agensys Inc Pharmaceutical compositions comprising anti-191p4d12 antibody drug conjugates and methods of use thereof
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CA3117710A1 (en) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
BR112021011393A2 (pt) 2018-12-13 2021-08-31 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
WO2020131598A1 (en) 2018-12-18 2020-06-25 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2020127411A1 (en) 2018-12-19 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
AU2019402189B2 (en) 2018-12-20 2023-04-13 Novartis Ag Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
IL282838B2 (en) 2018-12-21 2025-05-01 Valerio Therapeutics Conjugated nucleic acid molecules and their uses
CN113474048A (zh) 2018-12-21 2021-10-01 Aim免疫科技有限公司 用于癌症治疗的组合物和方法
CA3119582A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1.beta. binding antibodies
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
US20200369762A1 (en) 2018-12-21 2020-11-26 Novartis Ag Use of il-1beta binding antibodies
CN109593135B (zh) * 2018-12-29 2021-01-15 百奥赛图江苏基因生物技术有限公司 抗人pd-l1单克隆抗体及其应用
CN111423510B (zh) 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
WO2020149712A1 (ko) 2019-01-17 2020-07-23 오토텔릭바이오 주식회사 암 치료용 조성물
JP7636330B2 (ja) 2019-01-17 2025-02-26 ジョージア テック リサーチ コーポレイション 酸化コレステロールを含有する薬物送達システム
AU2020208637A1 (en) 2019-01-18 2021-09-09 Dracen Pharmaceuticals, Inc. Combinaton therapy with a don prodrug and an immune checkpoint inhibitor
ES3033655T3 (en) 2019-01-30 2025-08-06 Inst Nat Sante Rech Med Methods and compositions for identifying whether a subject suffering from a cancer will achieve a response with an immune-checkpoint inhibitor
JP2022524921A (ja) 2019-02-01 2022-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド がんを治療するための、ペムブロリズマブと組み合わせたベランタマブマフォドチン
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
JP7662528B2 (ja) 2019-02-12 2025-04-15 スミトモ ファーマ アメリカ， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
WO2020165370A1 (en) 2019-02-13 2020-08-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
US20220107320A1 (en) 2019-02-15 2022-04-07 Incelldx, Inc. Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein
AU2020222345B2 (en) 2019-02-15 2022-11-17 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7488826B2 (ja) 2019-02-15 2024-05-22 ノバルティス アーゲー 置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
WO2020176771A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
MX2021010228A (es) 2019-02-28 2021-10-26 Regeneron Pharma Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel.
WO2020180727A1 (en) 2019-03-06 2020-09-10 Regeneron Pharmaceuticals, Inc. Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
US20230083015A1 (en) 2019-03-26 2023-03-16 The Regents Of The University Of Michigan Small molecule degraders of stat3
KR20220012227A (ko) 2019-03-28 2022-02-03 오리오니스 바이오사이언시즈 인코포레이티드 Clec9a-기반 키메라 단백질 복합체
CA3133643A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Therapeutic interferon alpha 1 proteins
BR112021019178A2 (pt) 2019-03-29 2021-12-07 Centre Nat Rech Scient Variantes de interleucina-2 com atividade biológica modificada
WO2020205467A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Stat3 protein degraders
EP3947640A4 (de) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. Verfahren zur bestimmung der progression eines primären melanoms
WO2020205688A1 (en) 2019-04-04 2020-10-08 Merck Sharp & Dohme Corp. Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
CN113811329B (zh) 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
EP3725370A1 (de) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modifizierte anti-pd-l1-antikörper und verfahren und verwendungen zur behandlung einer neurodegenerativen erkrankung
EP3963109A1 (de) 2019-04-30 2022-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur behandlung von melanom
WO2020230142A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
EP3976090A1 (de) 2019-05-24 2022-04-06 Pfizer Inc. Kombinationstherapien mit cdk-hemmern
TWI781405B (zh) * 2019-05-29 2022-10-21 日商大鵬藥品工業股份有限公司 使用磺醯胺化合物與免疫調節劑之癌併用療法
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
US20220304984A1 (en) 2019-06-12 2022-09-29 Vanderbilt University Amino acid transport inhibitors and the uses thereof
WO2020252336A1 (en) 2019-06-12 2020-12-17 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
CN114206379A (zh) 2019-06-18 2022-03-18 爱尔兰詹森科学公司 乙型肝炎病毒(hbv)疫苗和抗pd-1抗体的组合
EP3986454A1 (de) 2019-06-18 2022-04-27 Janssen Sciences Ireland Unlimited Company Kombination aus hepatitis-b-virus (hbv) -impfstoffen und anti-pd-1- oder anti-pd-l1-antikörper
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
JP7329173B2 (ja) 2019-06-25 2023-08-18 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
JP2022539178A (ja) 2019-06-26 2022-09-07 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｉｌ１ｒａｐ結合タンパク質
AU2020302928A1 (en) 2019-06-27 2022-02-03 Medstar Health, Inc. HDAC6-activated macrophages, compositions, and uses thereof
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
US11529350B2 (en) 2019-07-03 2022-12-20 Sumitomo Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
US20220356255A1 (en) * 2019-07-15 2022-11-10 Capella Bioscience Ltd Anti-pd-l1 antibodies
JP7738909B2 (ja) 2019-07-16 2025-09-16 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Ｅｅｄ阻害剤としてのイミダゾピリミジンおよびその使用
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
AU2020324388A1 (en) 2019-08-02 2022-02-24 Mersana Therapeutics, Inc. Bis-[N-((5-carbamoyl)-1H-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as STING (Stimulator of Interferon Genes) agonists for the treatment of cancer
JP7537766B2 (ja) 2019-08-09 2024-08-21 国立研究開発法人理化学研究所 人工アジュバントベクター細胞と免疫賦活化剤との併用
CA3151824A1 (en) 2019-08-27 2021-03-04 The Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US12121565B2 (en) 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
EP4031178A1 (de) 2019-09-16 2022-07-27 Surface Oncology, Inc. Anti-cd39-antikörperzusammensetzungen und verfahren
CA3151022A1 (en) 2019-09-17 2021-03-25 Bial - R&D Investments, S.A. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
EP4031540A1 (de) 2019-09-17 2022-07-27 Bial-R&D Investments, S.A. Substituierte, gesättigte und ungesättigte n-heterozyklische carboxamide und verwandte verbindungen zur verwendung bei der behandlung von medizinischen beschwerden
MX2022003237A (es) 2019-09-17 2022-07-04 Bial R&D Invest S A Imidazol carboxamidas sustituidas y su uso en el tratamiento de trastornos medicos.
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4031241A1 (de) 2019-09-19 2022-07-27 The Regents Of The University Of Michigan Spirocyclische androgenrezeptorproteindegrader
CN115087671A (zh) 2019-09-25 2022-09-20 表面肿瘤学公司 抗il-27抗体及其用途
CA3155173A1 (en) 2019-09-27 2021-04-01 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
US20220354811A1 (en) 2019-10-03 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
US12380963B2 (en) 2019-10-14 2025-08-05 The Medical College Of Wisconsin, Inc. Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
US20240301497A1 (en) 2019-10-17 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing nasal intestinal type adenocarcinomas
WO2021079195A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
IL292347A (en) 2019-10-21 2022-06-01 Novartis Ag Combination treatments with ventoclax and tim-3 inhibitors
WO2021078910A1 (en) 2019-10-22 2021-04-29 Institut Curie Immunotherapy targeting tumor neoantigenic peptides
WO2021081353A1 (en) 2019-10-23 2021-04-29 Checkmate Pharmaceuticals, Inc. Synthetic rig-i-like receptor agonists
CN114829357A (zh) 2019-10-28 2022-07-29 中国科学院上海药物研究所 五元杂环氧代羧酸类化合物及其医药用途
WO2021083959A1 (en) 2019-10-29 2021-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
KR20220092540A (ko) 2019-10-29 2022-07-01 에자이 알앤드디 매니지먼트 가부시키가이샤 암을 치료하기 위한 pd-1 길항제, vegfr/fgfr/ret 티로신 키나제 억제제 및 cbp/베타-카테닌 억제제의 조합물
US12514927B2 (en) 2019-10-30 2026-01-06 Duke University Immunotherapy with combination therapy comprising an immunotoxin
CN114846135A (zh) 2019-11-04 2022-08-02 杜克大学 原发性和转移性癌症的治疗
TW202132573A (zh) 2019-11-07 2021-09-01 美商昂克賽納醫療公司 腫瘤微環境之分類
KR20220113390A (ko) 2019-11-13 2022-08-12 다이호야쿠힌고교 가부시키가이샤 Lsd1 억제제를 사용하여 lsd1-관련 질환 및 장애를 치료하는 방법
JP2023502264A (ja) 2019-11-22 2023-01-23 スミトモ ファーマ オンコロジー， インコーポレイテッド 固体用量医薬組成物
EP3824954A1 (de) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Vorrichtung, einrichtung und verfahren zur ministrahl-strahlentherapie
TW202132297A (zh) 2019-11-22 2021-09-01 美商施萬生物製藥研發Ｉｐ有限責任公司 經取代吡啶及使用方法
WO2021108025A1 (en) 2019-11-26 2021-06-03 Massachusetts Institute Of Technology Cell-based cancer vaccines and cancer therapies
GB201917252D0 (en) * 2019-11-27 2020-01-08 Pharmaceutic compositions
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2021113679A1 (en) 2019-12-06 2021-06-10 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
WO2021126725A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物
AU2020408198A1 (en) 2019-12-19 2022-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
CN115052662A (zh) 2019-12-20 2022-09-13 诺华股份有限公司 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
US20230140132A1 (en) 2020-01-07 2023-05-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
AU2021206256A1 (en) 2020-01-10 2022-07-28 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of immunotherapy agents across the blood-brain barrier to treat brain cancer
IL293752A (en) 2020-01-17 2022-08-01 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
US20230076415A1 (en) 2020-01-17 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
AU2021211669A1 (en) * 2020-01-21 2022-08-25 Bolt Biotherapeutics, Inc. Anti-PD-L1 antibodies
EP4097234A1 (de) 2020-01-28 2022-12-07 Université de Strasbourg Antisense-oligonukleotid mit abzielung auf linc00518 zur behandlung von melanomen
US20230067202A1 (en) 2020-01-28 2023-03-02 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
AU2021215332A1 (en) 2020-02-04 2022-08-18 BioNTech SE Antibodies for use in therapy
EP4100126A1 (de) 2020-02-05 2022-12-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur unterbrechung einer behandlung mit einem tyrosinkinaseinhibitor (tki)
EP4110955A1 (de) 2020-02-28 2023-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren zur diagnose, prognose und verwaltung der behandlung von brustkrebs
WO2022074464A2 (en) 2020-03-05 2022-04-14 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
US12522623B2 (en) 2020-03-26 2026-01-13 Regents Of The University Of Michigan Small molecule STAT protein degraders
TW202204339A (zh) 2020-03-31 2022-02-01 美商施萬生物製藥研發 Ip有限責任公司 經取代的嘧啶及使用方法
EP4126065A1 (de) 2020-04-02 2023-02-08 Mersana Therapeutics, Inc. Antikörper-wirkstoff-konjugate mit sting-agonisten
US20230149543A1 (en) 2020-04-14 2023-05-18 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
AU2021256652A1 (en) 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
JP2023521227A (ja) 2020-04-14 2023-05-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 癌の併用療法
EP4135847A4 (de) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus-impfstoff
WO2021216488A1 (en) 2020-04-21 2021-10-28 Regeneron Pharmaceuticals, Inc. Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
AU2021264216A1 (en) 2020-04-30 2022-11-10 Vlp Therapeutics, Inc. Cytokine immunotherapy
EP4137156A4 (de) 2020-05-01 2024-10-16 The University of Tokyo Prophylaktikum und therapeutikum
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
AU2021268614A1 (en) 2020-05-06 2022-12-08 Merck Sharp & Dohme Llc IL4I1 inhibitors and methods of use
CN116323647A (zh) 2020-05-13 2023-06-23 博纳姆治疗公司 蛋白质复合物的组合物及其使用方法
JP7776145B2 (ja) 2020-05-13 2025-11-26 マサチューセッツ インスティテュート オブ テクノロジー ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
AU2021275489A1 (en) 2020-05-20 2022-12-01 Centre National De La Recherche Scientifique - Cnrs - Single domain antibodies and their use in cancer therapies
TWI899236B (zh) 2020-05-26 2025-10-01 美商再生元醫藥公司 通過投予pd-1抑制劑治療子宮頸癌的方法
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
JP2023530275A (ja) 2020-06-10 2023-07-14 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤として有用なナフチリジン誘導体
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
MX2022015852A (es) 2020-06-23 2023-01-24 Novartis Ag Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
CR20230025A (es) 2020-06-26 2023-10-05 Amgen Inc Muteínas de il-10 y proteínas de fusión de las mismas referencia cruzada a solicitudes relacionadas
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
AU2021305234A1 (en) 2020-07-10 2023-02-09 Precigen, Inc. Fusion constructs and methods of using thereof
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
JP7819176B2 (ja) 2020-08-03 2026-02-24 ノバルティス アーゲー ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US12516307B2 (en) 2020-08-18 2026-01-06 Onchilles Pharma, Inc. Modified porcine pancreatic elastase proteins
MA71214A (fr) 2020-08-26 2025-04-30 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer par administration d'un inhibiteur de pd-1
WO2022049526A1 (en) 2020-09-02 2022-03-10 Pharmabcine Inc. Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer
KR20230061499A (ko) 2020-09-03 2023-05-08 리제너론 파마슈티칼스 인코포레이티드 Pd-1 저해제 투여에 의한 암 통증 치료 방법
CN111920948B (zh) * 2020-09-25 2021-02-02 安可瑞(山西)生物细胞有限公司 包含免疫细胞的药物组合物用于治疗癌症
EP4221842A4 (de) 2020-10-02 2024-11-20 Dracen Pharmaceuticals, Inc. Lyophilisierte zusammensetzung enthaltend (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoat zur subkutanen verabreichung und ihre verwendung
WO2022079270A1 (en) 2020-10-16 2022-04-21 Université D'aix-Marseille Anti-gpc4 single domain antibodies
CA3196243A1 (en) 2020-10-20 2022-04-28 Angela Marinetti Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
IL301907A (en) 2020-10-23 2023-06-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for lung cancer
US20230330081A1 (en) 2020-10-28 2023-10-19 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
US20230416838A1 (en) 2020-11-16 2023-12-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
EP4244391A1 (de) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur vorhersage und behandlung von uvealem melanom
US20230416196A1 (en) 2020-11-18 2023-12-28 Institut Curie Dimer of biguanidines and their therapeutic uses
WO2022122765A2 (en) 2020-12-07 2022-06-16 Genmab A/S Antibody and taxane combination therapy
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
JP2024505428A (ja) 2021-01-14 2024-02-06 アンスティテュ キュリー Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
WO2022165260A1 (en) 2021-01-29 2022-08-04 Iovance Biotherapeutics, Inc. Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20240423972A1 (en) 2021-02-01 2024-12-26 Yale University Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
PH12023552345A1 (en) 2021-03-02 2024-04-22 Glaxosmithkline Ip Dev Ltd Substituted pyridines as dnmt1 inhibitors
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
EP4308118A1 (de) 2021-03-17 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren und zusammensetzungen zur melanombehandlung
US20240310266A1 (en) 2021-03-18 2024-09-19 Novartis Ag Biomarkers for cancer and methods of use thereof
WO2022204672A1 (en) 2021-03-23 2022-09-29 Regeneron Pharmaceuticals, Inc. Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
US20240344138A1 (en) 2021-03-25 2024-10-17 Feng Biosciences, Inc Targeted therapies in cancer
BR112023019847A2 (pt) 2021-03-29 2023-11-07 Juno Therapeutics Inc Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
WO2022208353A1 (en) 2021-03-31 2022-10-06 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3214729A1 (en) 2021-04-08 2022-10-13 Marilena GALLOTTA Combination therapies with cbl-b inhibitor compounds
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
US20240158861A1 (en) 2021-04-23 2024-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cell senescence accumulation related disease
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
JP2024516970A (ja) 2021-05-07 2024-04-18 サーフィス オンコロジー， エルエルシー 抗ｉｌ－２７抗体及びその使用
EP4337763A1 (de) 2021-05-10 2024-03-20 Institut Curie Verfahren zur behandlung von krebs, entzündlichen erkrankungen und autoimmunerkrankungen
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
AU2022281461A1 (en) 2021-05-25 2024-01-04 Edelweiss Immune Inc C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
EP4346904A1 (de) 2021-06-03 2024-04-10 Synthorx, Inc. Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und cetuximab
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
AU2022288058A1 (en) 2021-06-07 2023-11-16 Agonox, Inc. Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
JP2024527322A (ja) 2021-07-02 2024-07-24 イエール ユニバーシティ がんを治療するための組成物および方法
IL310201A (en) 2021-07-19 2024-03-01 Regeneron Pharma Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment
US20250009877A1 (en) 2021-07-30 2025-01-09 Seagen Inc. Treatment for cancer
JP2024528217A (ja) 2021-08-03 2024-07-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗体および使用方法
WO2023011879A1 (en) 2021-08-05 2023-02-09 Institut Curie Scanning dynamic device for minibeams production
JP2024534265A (ja) 2021-08-23 2024-09-18 イミュニタス セラピューティクス，インコーポレーテッド 抗ｃｄ１６１抗体及びその使用
EP4393947A4 (de) 2021-08-25 2025-07-30 Toagosei Co Ltd Anti-pd-1-signalpeptidantikörper und verwendung davon
JP2024532621A (ja) 2021-08-31 2024-09-05 イエール ユニバーシティ がんを治療するための組成物および方法
US20240316061A1 (en) 2021-09-17 2024-09-26 Institut Curie Bet inhibitors for treating pab1 deficient cancer
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
US20250002600A1 (en) 2021-10-06 2025-01-02 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
WO2023057535A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
US20240426823A1 (en) 2021-11-03 2024-12-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
US20250019708A1 (en) 2021-11-19 2025-01-16 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
IL313439A (en) 2021-12-16 2024-08-01 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
EP4452327A1 (de) 2021-12-20 2024-10-30 Synthorx, Inc. Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und pembrolizumab
WO2023118165A1 (en) 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CA3243281A1 (en) 2022-01-28 2023-08-03 Georgiamune Inc. ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1 PD-1 AGONISTS
CA3243419A1 (en) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. CYTOKINE-ASSOCIATED TUMOR-INFILTRATING LYMPHOCYTE COMPOSITIONS AND PROCESSES
US20250152643A1 (en) 2022-02-17 2025-05-15 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
CN119013022A (zh) 2022-03-14 2024-11-22 来凯有限公司 癌症的组合治疗
JP2025510795A (ja) 2022-03-24 2025-04-15 アンスティテュ・クリー 神経膠芽腫における腫瘍転位因子由来のネオ抗原ペプチドを標的化する免疫療法
US20250213614A1 (en) 2022-03-31 2025-07-03 Institut Curie Modified RELA Protein for Inducing Interferon Expression and Engineered Immune Cells with Improved Interferon Expression
US20250241949A1 (en) 2022-04-07 2025-07-31 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
WO2023194607A1 (en) 2022-04-07 2023-10-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
WO2024033399A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024040264A1 (en) 2022-08-19 2024-02-22 Massachusetts Institute Of Technology Compositions and methods for targeting dendritic cell lectins
TW202416953A (zh) 2022-08-26 2024-05-01 日商衛材R&D企管股份有限公司 抗體藥物複合物
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
EP4593868A1 (de) 2022-09-26 2025-08-06 Institut Curie Myeloidzellen zur expression von il-2 und verwendungen davon zur schnellen antikrebstherapie
EP4602078A2 (de) 2022-10-11 2025-08-20 Yale University Zusammensetzungen und verfahren zur verwendung zellpenetrierender antikörper
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
CN120569191A (zh) 2022-11-23 2025-08-29 乔治亚大学研究基金公司 用于增加免疫应答的组合物及其使用方法
CN120858108A (zh) 2023-01-06 2025-10-28 拉森医疗公司 抗il-18bp抗体
WO2024148243A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
WO2024150525A1 (ja) 2023-01-12 2024-07-18 国立大学法人山口大学 抗ネコｐｄ－１抗体
IL322179A (en) 2023-01-30 2025-09-01 Kymab Ltd Antibodies
WO2024184417A1 (en) 2023-03-07 2024-09-12 Photocure Asa Therapy for bladder cancer
JPWO2024190329A1 (de) 2023-03-13 2024-09-19
EP4682255A1 (de) 2023-03-13 2026-01-21 Toagosei Co., Ltd. Zusammensetzung und verwendung davon
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
EP4688161A1 (de) 2023-03-29 2026-02-11 Merck Sharp & Dohme LLC Il4i1-inhibitoren und verfahren zur verwendung
AU2024252845A1 (en) 2023-04-06 2025-10-16 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
EP4688160A1 (de) 2023-04-06 2026-02-11 Genmab A/S Multispezifische bindemittel gegen pd-l1 und cd137 zur behandlung von krebs
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
EP4701650A2 (de) 2023-04-26 2026-03-04 Isabella Pharma B.V. Verfahren zur behandlung von krebs durch verabreichung immunogener zusammensetzungen und eines pd-1-inhibitors
EP4704807A1 (de) 2023-05-03 2026-03-11 IOX Therapeutics Limited Liposomale inkt-zellmodulatorzusammensetzungen und verfahren zur verwendung
TW202509069A (zh) 2023-05-04 2025-03-01 美商諾瓦森塔股份有限公司 抗cd161抗體及其使用方法
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
CN119451994A (zh) 2023-05-31 2025-02-14 Fbd生物制品有限公司 靶向cd47/pd-l1的蛋白质复合物和其使用方法
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2025046272A1 (en) 2023-08-31 2025-03-06 Taiho Pharmaceutical Co., Ltd. Methods of treating cancer using futibatinib and pembrolizumab
WO2025049858A1 (en) 2023-09-01 2025-03-06 Amgen Inc. Molecules for treatment of cancer
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
US20250114468A1 (en) 2023-10-09 2025-04-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
TW202523359A (zh) 2023-10-24 2025-06-16 英商阿斯特捷利康英國股份有限公司 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合
WO2025096843A1 (en) 2023-11-03 2025-05-08 Amgen Inc. Bispecific molecules
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
EP4574165A1 (de) 2023-12-21 2025-06-25 Egle Therapeutics Immunozytokine zur krebsbehandlung
WO2025133175A1 (en) 2023-12-21 2025-06-26 Egle Therapeutics Immunocytokine for cancer treatment
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
WO2025158077A1 (en) 2024-01-26 2025-07-31 Institut Curie Lipid degraders to trigger ferroptosis in cancer
WO2025202222A1 (en) 2024-03-25 2025-10-02 Institut National de la Santé et de la Recherche Médicale Therapeutic use of sting and tlrs agonists to induce p16 expression in immune cells
WO2025207705A1 (en) 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025202450A1 (en) 2024-03-28 2025-10-02 Institut Curie Myeloid cells modified by cytokine chimeric receptor and uses thereof
EP4624494A1 (de) 2024-03-29 2025-10-01 Institut Curie Her2-einzeldomänenantikörper und verwendungen davon
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025210252A1 (en) 2024-04-05 2025-10-09 Institut Curie Modulators of fam118b protein for use in therapy
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
WO2025259515A2 (en) 2024-06-11 2025-12-18 Amgen Inc. Combination treatment
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
EP4681780A1 (de) 2024-07-18 2026-01-21 Egle Therapeutics Immunozytokine zur krebsbehandlung
WO2026017820A1 (en) 2024-07-18 2026-01-22 Egle Therapeutics Fusion protein for cancer treatment
EP4707295A1 (de) 2024-09-05 2026-03-11 Egle Therapeutics Interleukin-2-varianten mit modifizierter biologischer aktivität
EP4707296A1 (de) 2024-09-05 2026-03-11 Egle Therapeutics Interleukin-2-varianten mit modifizierter biologischer aktivität
WO2026055167A1 (en) 2024-09-05 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and use of biomarkers in uses thereof
WO2026055168A1 (en) 2024-09-06 2026-03-12 Surface Oncology, LLC Anti-il-27 antibodies and uses and doses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (de) 1956-03-21 1900-01-01
US3095355A (en) 1961-10-12 1963-06-25 Revlon Aerosol composition
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3454275B2 (ja) 1992-06-05 2003-10-06 佑 本庶 プログラムされた細胞死に関連した新規なポリペプチドおよびそれをコードするｄｎａ
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
WO1994004670A1 (en) * 1992-08-26 1994-03-03 President And Fellows Of Harvard College Use of the cytokine ip-10 as an anti-tumor agent
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
DE4431401A1 (de) * 1994-08-24 1996-02-29 Max Delbrueck Centrum Lebendvakzine gegen Tumorerkrankungen
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
WO1997007671A1 (en) 1995-08-29 1997-03-06 Kirin Beer Kabushiki Kaisha Chimeric animal and method for constructing the same
ES2533255T3 (es) * 1998-07-13 2015-04-08 Board Of Regents, The University Of Texas System Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer
CA2352783C (en) * 1998-12-03 2012-04-10 The Regents Of The University Of California Stimulation of t cells against self antigens using ctla-4 blocking agents
US7041474B2 (en) 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
EP1053751A1 (de) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Zusammensetzungen und Verfahren zur Behandlung von Zellproliferationskrankheiten
FR2794025A1 (fr) * 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
IL147972A0 (en) * 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Ge Pd-1, a receptor for b7-4 and uses therefor
CA2381770C (en) 1999-08-24 2007-08-07 Medarex, Inc. Human ctla-4 antibodies and their uses
GB9927328D0 (en) * 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
JP3904374B2 (ja) * 2000-02-29 2007-04-11 独立行政法人科学技術振興機構 キラー活性を増強したリンパ球
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7432059B2 (en) 2000-06-28 2008-10-07 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that upmodulate T cell activation in the presence of a PD-1 mediated signal
US7132109B1 (en) * 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
DE60137146D1 (de) * 2000-10-20 2009-02-05 Tsuneya Ohno Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
EP2388590A1 (de) 2001-04-02 2011-11-23 Dana Farber Cancer Institute PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002258941A1 (en) * 2001-04-20 2002-11-05 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
WO2003006636A1 (de) 2001-07-12 2003-01-23 Genethor Gmbh Reduktion der stimulationsfähigkeit von antigen präsentierenden zellen
EP1445264B1 (de) 2001-07-31 2011-09-14 Ono Pharmaceutical Co., Ltd. Pd-1-spezifische substanz
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
JP4488740B2 (ja) 2001-11-13 2010-06-23 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫細胞活性化を調節する作用剤およびその使用方法
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2489803A1 (en) 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
JP4511943B2 (ja) * 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
ES2729974T3 (es) * 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
EP1591627A1 (de) 2004-04-27 2005-11-02 Siemens Aktiengesellschaft Regeleinrichtung für einen Kompressor sowie Verwendung eines Bragg-Gitter-Sensors bei einer Regeleinrichtung
US20090123413A1 (en) 2004-08-23 2009-05-14 Britta Hardy Use of bat monoclonal antibody for immunotherapy
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CN103059138B (zh) 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling

Also Published As

Publication number Publication date
EP1537878A1 (de) 2005-06-08
FR15C0088I1 (fr) 2016-02-12
EP2206517A1 (de) 2010-07-14
SI2206517T1 (sl) 2023-12-29
JP5159730B2 (ja) 2013-03-13
US9393301B2 (en) 2016-07-19
US8168179B2 (en) 2012-05-01
US9439962B2 (en) 2016-09-13
EP1537878A4 (de) 2006-11-29
DE60334303D1 (de) 2010-11-04
US20150093380A1 (en) 2015-04-02
JP6035372B2 (ja) 2016-11-30
US20140314714A1 (en) 2014-10-23
EP2243493A1 (de) 2010-10-27
EP1537878B1 (de) 2010-09-22
US20060110383A1 (en) 2006-05-25
DE10161767T1 (de) 2018-06-07
EP2206517B1 (de) 2023-08-02
HUE10161767T1 (hu) 2019-03-28
US20090297518A1 (en) 2009-12-03
PT2206517T (pt) 2023-11-07
ES2654064T3 (es) 2024-03-13
AU2003281200A1 (en) 2004-01-23
JP5885764B2 (ja) 2016-03-15
JP2015163631A (ja) 2015-09-10
DK2206517T3 (da) 2023-11-06
PT1537878E (pt) 2010-11-18
US8728474B2 (en) 2014-05-20
JP2021080301A (ja) 2021-05-27
ES2654064T1 (es) 2018-02-12
US9402899B2 (en) 2016-08-02
HUS1600004I1 (hu) 2016-02-29
DK2206517T1 (da) 2018-02-05
JP2014065748A (ja) 2014-04-17
CY20182200001T2 (el) 2018-06-27
US20160158355A1 (en) 2016-06-09
JP2012236861A (ja) 2012-12-06
US20170051060A1 (en) 2017-02-23
DK1537878T3 (da) 2011-01-24
EP3287144A1 (de) 2018-02-28
FI2206517T3 (fi) 2023-10-19
JP2009286795A (ja) 2009-12-10
JP5701266B2 (ja) 2015-04-15
US20150197572A1 (en) 2015-07-16
JP4409430B2 (ja) 2010-02-03
LU92905I2 (fr) 2016-02-10
US9073994B2 (en) 2015-07-07
US7595048B2 (en) 2009-09-29
JP2019094340A (ja) 2019-06-20
US20160158356A1 (en) 2016-06-09
JP6258428B2 (ja) 2018-01-10
ES2350687T3 (es) 2011-01-26
HUE065675T2 (hu) 2024-06-28
LU92940I2 (en) 2016-03-07
US20200062846A1 (en) 2020-02-27
FR16C0001I1 (fr) 2016-02-12
JP2016210817A (ja) 2016-12-15
US20110081341A1 (en) 2011-04-07
JP6559207B2 (ja) 2019-08-14
US9067999B1 (en) 2015-06-30
WO2004004771A1 (ja) 2004-01-15
JPWO2004004771A1 (ja) 2005-11-04
JP2018039835A (ja) 2018-03-15
HUS1500066I1 (hu) 2016-02-29

Similar Documents

Publication Publication Date Title
LU92905I2 (fr) Nivolumab
MY196582A (en) PD-1/PD-L1 Inhibitors
EP4600247A3 (de) Pd-1/pd-l1-inhibitoren
EP4234030A3 (de) Pd-1/pd-l1-inhibitoren
EP2037922A4 (de) Prolyl-hydroxylase-hemmer
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
EP1551812A4 (de) Mitotische kinesinhemmer
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE447577T1 (de) Mitotische kinesin-hemmer
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
DK1196414T3 (da) Prolægemiddel af carbamathæmmer for IMPDH
EA200501928A1 (ru) Пирролодигидроизохинолины как ингибиторы pde10
TW200700422A (en) Compounds for inhibiting ksp kinesin activity
TW200700066A (en) Compounds for inhibiting ksp kinesin activity
ATE443044T1 (de) Tace inhibitoren
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
DE602004025586D1 (de) Alpha-aminoamid derivate zur verwendung als anti-inflammatorische wirkstoffe
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
EA202091694A1 (ru) Ингибиторы pd-1/pd-l1
DE602004007284D1 (de) Pyrimidine als inhibitoren von phosphoinositid-3-kinasen (pi3k)
PT1244614E (pt) Inibidores de triptase
EA202092733A1 (ru) Ингибиторы pd-1/pd-l1
MXPA05007846A (es) Derivados de diazepanes utiles como inhibidores de lfa.
WO2006132681A3 (en) Methods for identifying compounds that inhibit hiv infection

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1537878

Country of ref document: EP